Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 11
Submit an article Journal homepage
517
Views
22
CrossRef citations to date
0
Altmetric
Research Article

Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy

Ellen KochDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
,
Sara K. StoryDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
&
Larisa J. GeskinDepartment of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USACorrespondence[email protected]
Pages 2448-2451 | Received 30 Nov 2012, Accepted 20 Feb 2013, Published online: 08 Apr 2013

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Tarsheen Sethi, Francesca Montanari & Francine Foss. (2022) Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion on Drug Safety 21:5, pages 653-660.
Read now
Zhao Jennifer C, Jaszczur Sara Mohamed, Afifi Salma & Foss Francine. (2020) Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Expert Review of Hematology 13:6, pages 577-583.
Read now
Francine M. Foss, Terri L. Parker, Michael Girardi & Anlong Li. (2019) Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 60:12, pages 2927-2930.
Read now
Owen A. O’Connor, Jennifer Amengual, Donald Colbourn, Changchun Deng & Ahmed Sawas. (2017) Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. Leukemia & Lymphoma 58:11, pages 2548-2557.
Read now
Jason B Kaplan, Joan Guitart & Francis J Giles. (2014) Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology 7:4, pages 481-493.
Read now
Michael Dickinson & Henry Miles Prince. (2014) Emerging drugs for T-cell lymphoma. Expert Opinion on Emerging Drugs 19:2, pages 201-213.
Read now

Articles from other publishers (16)

Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism 35 67 .
Enrica Marchi & Owen A. O’Connor. (2019) The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management. CA: A Cancer Journal for Clinicians 70:1, pages 47-70.
Crossref
Koichi Kitazume, Yuri Akagawa, Sachie Wada, Takayuki Suzuki & Akira Fujita. (2019) Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin. Case Reports in Oncology 12:2, pages 529-536.
Crossref
Francine M. Foss, Terri L. Parker, Michael Girardi & Anlong Li. (2018) Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma and Leukemia 18:11, pages e445-e447.
Crossref
Dai Maruyama, Hirokazu Nagai, Yoshinobu Maeda, Takahiko Nakane, Tatsu Shimoyama, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, Koji Izutsu, Ryuzo Ueda & Kensei Tobinai. (2017) Phase I/ II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma . Cancer Science 108:10, pages 2061-2068.
Crossref
Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen & Yi-Hsin Elsa Hsu. (2016) Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. PLOS ONE 11:10, pages e0161811.
Crossref
Jordan P. McPherson, Alaina Vrontikis, Courtney Sedillo, Ahmad S. Halwani & Jeffrey A. Gilreath. (2016) Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:2, pages e8-e11.
Crossref
Catherine G. Chung & Brian Poligone. (2015) Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy. Current Hematologic Malignancy Reports 10:4, pages 468-476.
Crossref
Jean L. Grem, Mary E. Kos, Ruby E. Evande, Jane L. Meza & James K. Schwarz. (2015) A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. Cancer 121:21, pages 3862-3868.
Crossref
Bhavik Desai & Thomas P. Sollecito. 2015. The ADA Practical Guide to Patients with Medical Conditions. The ADA Practical Guide to Patients with Medical Conditions 153 182 .
Lauren C. Hughey. (2015) Practical Management of CD30+ Lymphoproliferative Disorders. Dermatologic Clinics 33:4, pages 819-833.
Crossref
Chan Yoon CheahYasuhiro OkiMichelle A. Fanale. (2015) Novel Treatments for T-Cell Lymphoma. American Society of Clinical Oncology Educational Book:35, pages e468-e478.
Crossref
Philip M. Tedeschi, Yamini K. Kathari, Iqra N. Farooqi & Joseph R. Bertino. (2014) Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer Chemotherapy and Pharmacology 74:5, pages 1029-1032.
Crossref
Rakhshandra Talpur, Andrew Thompson, Pamela Gangar & Madeleine Duvic. (2014) Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 297-304.
Crossref
Michele Visentin, Ersin Selcuk Unal & I. David Goldman. (2014) The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro. Cancer Chemotherapy and Pharmacology 73:5, pages 1055-1062.
Crossref
. (2013) Pralatrexate. Reactions Weekly 1482:1, pages 33-33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.